Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909330 | 0.91 | CYP1A2 (0.38) | RORCABCG2DHODH | |
| SCHEMBL29909021 | 0.90 | ABCG2 (0.34) | RORCABCG2DHODHPDE5ANR1H2 | |
| SCHEMBL29909607 | 0.89 | ABCG2 (0.34) | ABCG2PTGS2PTGS1DHODHPDE5A | |
| SCHEMBL29909909 | 0.89 | DHODH (0.41) | RORCABCG2SCDPTGS2PTGS1 | |
| SCHEMBL29909927 | 0.89 | RORC (0.38) | RORCSCDPTGS2PTGS1TP53 | |
| SCHEMBL29909178 | 0.89 | ABCG2 (0.33) | ABCG2PTGS2DHODHPDE5A | |
| SCHEMBL30961045 | 0.88 | KCNH2 (0.34) | ABCG2DHODHPDE5A | |
| SCHEMBL29909623 | 0.88 | PTGDR2 (0.35) | ABCG2PTGS2PTGS1 | |
| SCHEMBL30961011 | 0.88 | NR1H2 (0.37) | RORCLRRK2SCDPTGS2PTGS1 | |
| SCHEMBL29909683 | 0.88 | RORC (0.34) | RORCABCG2DHODHPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | RORC 1542/4885LRRK2 832/4885ABCG2 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.